Endocrine Abstracts

Patients with diabetes mellitus (DM) type 2 is a group of high cardiovascular risk. The incidence of coronary heart disease in their 2–4 times higher than in the population without diabetes, 80% of cases of diabetes combined with hypertension. At the same time any change in lipid metabolism leads to increased cardiovascular risk in patients with type 2 diabetes. Statins is first-line drugs in patients with dyslipidemia.

Materials and methods: The study involved 15 patients with type 2 diabetes and dyslipidemia in mean age 59.8±1.03 years, among them, 11 women and four male. All patients was prescribed statins in mean dose 4 mg per day for 3 month. During the study were determined the levels of glycated hemoglobin (HbA1c) and lipid status before and after treatment.

Results: Analyzing the results obtained in the groups of patients a significant decrease in levels of total cholesterol, low-density lipoprotein. Triglyceride levels decreased to normal range after 3 months. Statistically significant increase in glycated hemoglobin was not confirmed.

Conclusions: Application of statin leads to the likely reduction in levels of total cholesterol, low density lipoprotein, indicating that effective treatment of dyslipidaemia in patients with type 2 diabetes. Statistically significant effect on glycated hemoglobin was not observed.